Compare Cytokinetics Inc (CYTK) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Solaredge Technologies Inc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Solaredge Technologies Inc trades at $32.21 (market cap $2.00B). The key difference: Cytokinetics Inc is far larger — about 4.3× Solaredge Technologies Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Solaredge Technologies Inc for 34 Days on average.
| CYTK | SEDG | |
|---|---|---|
Market Cap | $8.62B | $2.00B |
Volume | 2,594,626 | 2,739,860 |
Sector | Health | Energy |
52-Week High | $87.26 | $78.51 |
52-Week Low | $54.76 | $28.47 |
Typical Hold Time | 19 Days | 34 Days |
Enterprise Value | $8.72B | $1.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% today, amid bearish technical signals but strong analyst optimism. The stock shows negative profitability with a -1,321.12% net income margin and P/S ratio of 114, reflecting high growth expectations. Recent Phase 3 trial successes for aficamten in hypertrophic cardiomyopathy position the company for potential FDA approval and commercial expansion, driving the 97% buy rating consensus with a $112.60 price target.
The outlook balances clinical progress against financial strain. While aficamten's recent data and commercial launch of MYQORZO offer significant upside, persistent cash burn and high valuation multiples present substantial risk. Investors face binary outcomes dependent on regulatory success and market penetration versus ongoing operational losses.
SEDG trades at $32.47, down 2.08% on the day, with a bearish technical signal and negative profitability metrics. The company reported a net loss of $405.45M in 2025, though revenue grew to $1.18B from $901M in 2024. Recent news highlights an ongoing fraud investigation by Pomerantz Law Firm and ambitious long-term revenue targets of $2.4B by 2029, alongside new AI data center initiatives with NVIDIA.
The outlook remains challenging due to persistent losses and high debt, but analyst consensus suggests moderate upside to a $37.75 price target. Key risks include execution on growth plans, industry financing pressures, and legal scrutiny. The stock offers speculative appeal for investors betting on a turnaround in solar and AI power conversion markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
